eculizumab

Ligand id: 6884

Name: eculizumab

Classification
Compound class Antibody
Approved drug? Yes (FDA (2011), EMA (2007))
International Nonproprietary Names
INN number INN
8231 eculizumab
Synonyms
h5G1.1 | h5G1.1VHC | Soliris®
Comments
Eculizumab is a humanized monoclonal antibody targeting terminal complement activation, by binding to complement component C5 and inhibiting the production of C5a. It is the first approved therapy for paroxysmal nocturnal hemoglobinuria.
Eculizumab's developers, Alexion Pharmaceuticals have an improved version of eculizumab called ALXN1210 in their development pipeline (several Phase 3 studies underway). ALXN1210 has a longer circulating half-life than the originator, that allows for monthly dosing.
The evidence confirming C5, C5a and the C5a receptor as anti-inflammatory and anti-cancer drug targets is reviewed by Horiuchi and Tsukamoto (2016) [2].

Biosimilars:
ABP 959 (Amgen) is in Phase 3 development under the jurisdiction of the Australian New Zealand Clinical Trials Registry (trial ID ACTRN12616000509460).
BOW080 (Epirus Biopharmaceuticals) is in preclinical development- see
None of these biosimilars can be FDA approved until Alexion's exclusivity period (due to protection as an orphan drug) expires in March 2019. Eculizumab's patent protection ends in May 2020 (Europe) and March 2021 (US).
Database Links
Specialist databases
IMGT/mAb-DB 37
Other databases
GtoPdb PubChem SID 178103466
PubChem SID 178103466
Search PubMed clinical trials eculizumab
Search PubMed titles eculizumab
Search PubMed titles/abstracts eculizumab
Wikipedia Eculizumab